1. Home
  2. CGEM vs BBDC Comparison

CGEM vs BBDC Comparison

Compare CGEM & BBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEM
  • BBDC
  • Stock Information
  • Founded
  • CGEM 2016
  • BBDC 2006
  • Country
  • CGEM United States
  • BBDC United States
  • Employees
  • CGEM N/A
  • BBDC N/A
  • Industry
  • CGEM Biotechnology: Pharmaceutical Preparations
  • BBDC Diversified Financial Services
  • Sector
  • CGEM Health Care
  • BBDC Finance
  • Exchange
  • CGEM Nasdaq
  • BBDC Nasdaq
  • Market Cap
  • CGEM 955.5M
  • BBDC 1.0B
  • IPO Year
  • CGEM 2021
  • BBDC 2007
  • Fundamental
  • Price
  • CGEM $16.02
  • BBDC $9.70
  • Analyst Decision
  • CGEM Strong Buy
  • BBDC Hold
  • Analyst Count
  • CGEM 7
  • BBDC 2
  • Target Price
  • CGEM $31.67
  • BBDC $10.00
  • AVG Volume (30 Days)
  • CGEM 447.2K
  • BBDC 289.7K
  • Earning Date
  • CGEM 11-07-2024
  • BBDC 11-06-2024
  • Dividend Yield
  • CGEM N/A
  • BBDC 10.73%
  • EPS Growth
  • CGEM N/A
  • BBDC 21.55
  • EPS
  • CGEM N/A
  • BBDC 1.09
  • Revenue
  • CGEM N/A
  • BBDC $291,393,000.00
  • Revenue This Year
  • CGEM N/A
  • BBDC N/A
  • Revenue Next Year
  • CGEM N/A
  • BBDC N/A
  • P/E Ratio
  • CGEM N/A
  • BBDC $8.91
  • Revenue Growth
  • CGEM N/A
  • BBDC 5.26
  • 52 Week Low
  • CGEM $7.64
  • BBDC $8.55
  • 52 Week High
  • CGEM $30.19
  • BBDC $10.24
  • Technical
  • Relative Strength Index (RSI)
  • CGEM 47.78
  • BBDC 48.40
  • Support Level
  • CGEM $15.37
  • BBDC $9.57
  • Resistance Level
  • CGEM $17.19
  • BBDC $9.88
  • Average True Range (ATR)
  • CGEM 0.95
  • BBDC 0.17
  • MACD
  • CGEM 0.08
  • BBDC 0.01
  • Stochastic Oscillator
  • CGEM 37.10
  • BBDC 60.71

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

About BBDC Barings BDC Inc.

Barings BDC Inc operates as a closed-end, non-diversified investment company and has elected to be treated as a business development company. The company's investment objective is to generate current income by investing directly in privately held middle-market companies to help these companies fund acquisitions, growth, or refinancing. Barings employs fundamental credit analysis and targets investments in businesses with low levels of cyclicality and operating risk relative to other businesses in this market segment. The holding size of each position will generally be dependent upon a number of factors including total facility size, pricing and structure, and the number of other lenders in the facility.

Share on Social Networks: